Literature DB >> 18473407

Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity?

Carlos Robles-Jara1, Carlos Robles-Medranda, Manuel Moncayo, Byron Landivar, Johnny Parrales.   

Abstract

AIM: To compare the efficacy of a 7-d vs 10-d triple therapy regarding H pylori eradication, endoscopic findings and histological gastric inflammatory inactivation in the Ecuadorian population.
METHODS: 136 patients with dyspepsia and H pylori infection were randomized in 2 groups (68 per group): group 1, 7-d therapy; group 2, 10-d therapy. Both groups received the same medication and daily dosage: omeprazole 20 mg bid, clarithromycin 500 mg bid and amoxicillin 1 g bid. Endoscopy was performed for histological assessment and H pylori infection status before and 8 wk after treatment.
RESULTS: H pylori was eradicated in 68% of group 1 vs 83.8% of group 2 for the intention-to-treat analysis (ITT) (P = 0.03; OR = 2.48; 95% CI, 1.1-5.8), and 68% in group 1 vs 88% in group 2 for the per-protocol analysis (PP) (P = 0.008; OR = 3.66; 95% CI, 1.4-10). Endoscopic gastric mucosa normalization was observed in 56.9% in group 1 vs 61.2% in group 2 for ITT, with similar results for the PP, the difference being statistically not significant. The rate of inflammatory inactivation was 69% in group 1 vs 88.7% in group 2 for ITT (P = 0.007; OR = 3.00; 95% CI, 1.2-7.5), and 69% in group 1 vs 96% in group 2 for PP (P = 0.0002; OR = 7.25; 95% CI, 2-26).
CONCLUSION: In this Ecuadorian population, the 10-d therapy was more effective than the 7-d therapy for H pylori eradication as well as for gastric mucosa inflammatory inactivation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18473407      PMCID: PMC2710724          DOI: 10.3748/wjg.14.2838

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

1.  A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection.

Authors:  X Calvet; N García; T López; J P Gisbert; E Gené; M Roque
Journal:  Aliment Pharmacol Ther       Date:  2000-05       Impact factor: 8.171

2.  A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology.

Authors:  Barik A Salih; M Fatih Abasiyanik; Huseyin Saribasak; Osman Huten; Ersan Sander
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

3.  [Efficacy of stool antigen and serologic tests in the diagnosis of Helicobacter pylori in Ecuadorian population].

Authors:  Néstor A Gómez; Ludwig R Alvarez; Jorge A Zapatier; Paola E Vargas
Journal:  Rev Gastroenterol Mex       Date:  2005 Apr-Jun

Review 4.  The Sydney System: endoscopic division. Endoscopic appearances in gastritis/duodenitis.

Authors:  G N Tytgat
Journal:  J Gastroenterol Hepatol       Date:  1991 May-Jun       Impact factor: 4.029

5.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

6.  [Efficacy of the dosing regimen of pantoprazole 40 mg, amoxicillin 1000 mg and clarithromycin 500 mg, twice daily for 7 days, in the eradication of Helicobacter pylori in patients with peptic ulcer].

Authors:  Luiz Gonzaga Vaz Coelho; Angelo Alves de Mattos; Carlos Fernando Magalhães Francisconi; Luiz de Paula Castro; Suraia Boaventura André
Journal:  Arq Gastroenterol       Date:  2004-10-15

7.  Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials.

Authors:  L Laine; L Suchower; J Frantz; A Connors; G Neil
Journal:  Am J Gastroenterol       Date:  1998-11       Impact factor: 10.864

8.  Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients.

Authors:  N Broutet; S Tchamgoué; E Pereira; H Lamouliatte; R Salamon; F Mégraud
Journal:  Aliment Pharmacol Ther       Date:  2003-01       Impact factor: 8.171

9.  Characteristics of clinical Helicobacter pylori strains from Ecuador.

Authors:  Yvette J Debets-Ossenkopp; Germán Reyes; Janet Mulder; Birgit M aan de Stegge; José T A M Peters; Paul H M Savelkoul; J Tanca; Amado S Peña; Christina M J E Vandenbroucke-Grauls
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

10.  Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori.

Authors:  Engin Altintas; Orhan Sezgin; Oguz Ulu; Ozlem Aydin; Handan Camdeviren
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.